Shmuel Cabilly
Angel Investor
Rehovot, Israel
Shmuel Cabilly is a Series C investor in Rehovot focused on Health Care and Medical. Dr. Cabilly is a highly regarded scientist, an investor and an experienced Board Member of several companies. He is currently a Board Member of Medasense Biometrics Ltd. He previously worked for several companies including as the Co-Founder and a Chief Scientist of Ethrog Biotechnology which was sold to Invitrogen. Dr. Cabilly graduated fromthe Hebrew University (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production. This invention was patented in world patents “The old Cabilly” and “The New Cabilly patent”. Today there are already 20 drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Shmuel Cabilly invests in
Stages Shmuel Cabilly invests in
Countries Shmuel Cabilly invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series C
- $22M–$22M
Investment Focus
Industry
- Health Care 4 (80%)
- Medical 2 (40%)
- Artificial Intelligence 2 (40%)
- Sensor 1 (20%)
- Big Data 1 (20%)
Stage
- Series C 2 (40%)
- Series B 1 (20%)
- Funding Round 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- Israel 4 (80%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| DiA Imaging Analysis provides advanced AI-based ultrasound analysis smarter and accessible. It solves the two main challenges clinicians face when using ultrasound: acquiring the right image and automatically analyzing it, to find clinical abnormalities that today they are struggling to find visually. DiA's automated tools can be easily beadded to any ultrasound device or healthcare IT system, just like an App.The company holds FDA/CE Clearances for its cardiac toolbox, generating revenues and having thousands of users around the world. | $14M / Venture - Series Unknown / Aug 24, 2021 | ||
| Raziel Health’s mission is to bring world-class, disruptively less expensive healthcare to everyone, in the comfort of their home. Its unique, integrated system combines easy-to-use technologies that support positive patient experience, enable timely clinical intervention, and meet individual patient goals while using data analytics to supportwellness and disease management. | $22M / Series C / Dec 18, 2019 | ||
| Raziel's drug aims for fat melting by harnessing the body’s own natural healing power and delivering proven biological activity. | $22M / Series C / Dec 03, 2019 | ||
| Treato automatically collects the massive amount of patient-written health experiences from blogs and forums and, with advanced Natural Language Processing (NLP), extracts relevant information, connects the dots and creates the big picture of what people say about their medications and conditions.Treato's big data analytics are availablein a consumer site and as an in-depth service for pharmaceutical marketers.Treato's Consumer site ( | $14.5M / Series B / Apr 23, 2013 | ||
| Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedicationMedasense’s flagship product, the PMD-200 with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and aproprietary non-invasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate – a $5B market. The company’s pipeline cloud-based solutions for clinics and home, leveraging the NOL technology, addresses an additional $15B global market.The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing.Medasense was founded in 2008 and based in Ramat Gan, Tel Aviv, Israel. | $1M / Dec 01, 2008 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Shmuel Cabilly invest in?
Shmuel Cabilly invests primarily in Health Care, Medical and Artificial Intelligence startups, most often at Series C and Series B stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Shmuel Cabilly invest in?
Shmuel Cabilly typically joins rounds of $22M–$22M at Series C. These are whole funding-round sizes, not Shmuel Cabilly's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Shmuel Cabilly took part in.
How do I contact Shmuel Cabilly?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Shmuel Cabilly last invest?
The most recent investment recorded for Shmuel Cabilly closed in Aug 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
